Highly increased 125I-JR11 antagonist binding in vitro reveals novel indications for sst2 targeting in human cancers

Journal of Nuclear Medicine

Volumn 58, Issue 2, 2017, Pages 300-306

  Reubi, Jean Claude ^a   Waser, Beatrice ^a   Mäcke, Helmut ^b   Rivier, Jean ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Breast cancer; Cancer radiopeptide targeting; Renal cell cancer; Somatostatin sst2 receptors; Sst2 antagonist

Indexed keywords

HORMONE RECEPTOR BLOCKING AGENT; IODINE 125; JR 11; RADIOLIGAND; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; RADIOACTIVE IODINE; SOMATOSTATIN RECEPTOR;

ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BREAST CANCER; COLON CANCER; DRUG DETERMINATION; DRUG EFFECT; DRUG TARGETING; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; ISOTOPE LABELING; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; NONHODGKIN LYMPHOMA; PROSTATE CANCER; THYROID MEDULLARY CARCINOMA; ANTAGONISTS AND INHIBITORS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL CULTURE;

HUMANS; IODINE RADIOISOTOPES; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, SOMATOSTATIN; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 85012016529     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.177733     Document Type: Article

References (35)

1. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
2. Oberg KE, Reubi JC, Kwekkeboom DJ, et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139:742-753.
3. Ambrosini V, Fani M, Fanti S, et al. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52(suppl 2):42S-55S.
4. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
5. 90YDOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29: 2416-2423.
6. Strosberg J, Wolin E, Chasen B, et al. 177-Lu-dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: results of the phase III NETTER-1 trial [abstract]. Eur J Cancer. 2015;51:S710.
7. Waser B, Tamma ML, Cescato R, et al. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009;50:936-941.
8. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA. 2006;103:16436-16441.
9. 2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities. Biochem Pharmacol. 1996;51:71-76.
10. Perrin MH, Sutton SW, Cervini LA, et al. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropinreleasing factor receptors. J Pharmacol Exp Ther. 1999;288:729-734.
11. Cescato R, Maina T, Nock B, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318-326.
12. Hansen LS, Sparre-Ulrich AH, Christensen M, et al. N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor. Br J Pharmacol. 2016;173:826-838.
13. Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is clinically feasible. J Nucl Med. 2011; 52:1412-1417.
14. 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011;52:1886-1890.
15. Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248-1252.
16. Reubi JC, Maurer R, von Werder K, et al. Somatostatin receptors in human endocrine tumors. Cancer Res. 1987;47:551-558.
17. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50:5969-5977.
18. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging. 2003;30:781-793.
19. Körner M, Waser B, Reubi JC. Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors? Neuroendocrinology. 2015;101:45-57.
20. Reubi JC, Waser B. Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs. J Nucl Med. 2015;56:613-615.
21. Reubi JC, Schaer JC, Waser B, et al. Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282.
22. Albérini JL, Meunier B, Denzler B, et al. Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography. Breast Cancer Res Treat. 2000;61:21-32.
23. Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab. 1995;80:2806-2814.
24. Nilsson S, Reubi JC, Kalkner K, et al. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by (111-In)-labeled DTPA-D-(Phe-1)-octreotide scintigraphy. Cancer Res. 1995;55(suppl):5805s-5810s.
25. Reubi C, Gugger M, Waser B. Coexpressed peptide receptors in breast cancers as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging. 2002;29:855-862.
26. Reubi JC, Mazzucchelli L, Hennig I, et al. Local upregulation of neuropeptide receptors in host blood vessels around human colorectal cancers. Gastroenterology. 1996;110:1719-1726.
27. Reubi JC, Kvols L. Somatostatin receptors in human renal cell carcinomas. Cancer Res. 1992;52:6074-6078.
28. Reubi JC, Waser B, van Hagen M, et al. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer. 1992;50: 895-900.
29. Reubi JC, Chayvialle JA, Franc B, et al. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest. 1991;64:567-573.
30. Reubi JC, Laissue JA, Waser B, et al. Expression of somatostatin receptors in normal, inflamed and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci. 1994;733:122-137.
31. van Eijck CHJ, Krenning EP, Bootsma A, et al. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet. 1994;343:640-643.
32. Freudenberg LS, Gauler T, Gorges R, et al. Somatostatin receptor scintigraphy in advanced renal cell carcinoma: results of a phase II-trial of somatostatine analogue therapy in patients with advanced RCC. Nuklearmedizin. 2008;47: 127-131.
33. 68Ga DOTATOC PET/CT: a rare differential diagnosis to multiple primary pancreatic neuroendocrine tumors. Clin Nucl Med. 2014;39:713-716.
34. Vanhagen PM, Krenning EP, Reubi JC, et al. Somatostatin analogue scintigraphy of malignant lymphomas. Br J Haematol. 1993;83:75-79.
35. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1993;76: 1413-1417.